ABSTRACT
Sialylated HEG1 has been reported as a highly specific and sensitive mesothelioma marker but a comprehensive evaluation of its expression in carcinomas in different organs, various sarcomas and reactive mesothelial proliferations has not been reported. The aim of this study was to evaluate the clinical applicability of HEG1 as a marker in the diagnosis of mesothelioma. HEG1 immunoreactivity was evaluated in whole sections of 122 mesotheliomas, 75 pulmonary carcinomas, 55 other carcinomas, 16 mesenchymal tumors, and 24 reactive mesothelial proliferations and in tissue microarrays containing 70 epithelioid (EM), 36 biphasic (BM), and 2 sarcomatoid mesotheliomas (SM). In whole sections and tissue microarrays, respectively, membranous HEG1 was expressed in 93.0% and 85.5% of EM, 81.3% and 69.4% of BM, 0% and 0% of SM. HEG1 was not expressed in pulmonary adenocarcinomas. HEG1 was expressed as cytoplasmic immunoreactivity in pulmonary squamous cell carcinomas (21.7%). Membranous HEG1 staining was seen in ovarian carcinomas (66.7%), thyroid carcinomas (100%), reactive conditions (16.7%), and mesenchymal tumors (18.8%). The sensitivity of membranous HEG1 expression to distinguish EM/BM from all carcinomas was 88.8%. The specificity for the differential diagnosis between EM/BM and all carcinomas and pulmonary carcinomas was 92.3% and 98.7%, respectively.
Subject(s)
Carcinoma, Squamous Cell/diagnosis , Lung Neoplasms/diagnosis , Membrane Proteins/metabolism , Mesothelioma, Malignant/diagnosis , Carcinoma, Squamous Cell/pathology , Diagnosis, Differential , Epithelium/pathology , Humans , Immunohistochemistry , Lung Neoplasms/pathology , Membrane Proteins/genetics , Mesothelioma, Malignant/pathology , Tissue Array AnalysisABSTRACT
BACKGROUND: The confirmation of an appropriate resection margin from the tumor is crucial for reducing the risk of local recurrence after sublobar resection for pulmonary malignancies. PATIENTS AND METHODS: From October 2014 to April 2018, 66 operative cases in 64 patients( primary lung cancer 42, metastatic lung tumor 21, benign disease 3) were enrolled. In lung cancer, active limited resection was done in 29 and passive limited resection was done in 13. Preoperatively, each patient created several virtual sublobar resections by using 3-dimensional (3D) volume analyzer. We measured the surgical margin in each simulated sublobar resection and selected the most appropriate procedure. Surgical resection matched with virtual sublobar resection was done by using an infrared thoracoscopy with transbronchial indocyanine green (ICG) instillation. In lung cancer, we compared surgical outcomes between ICG cases and 47 historical segmentectomy cases. RESULTS: The types of sublobar resection were subsegmental resection in 5, simple segmentectomy in 15, complex segmentectomy in 16 and extended segmentectomy in 22 and anatomical super deep wedge resection in 8. The shortest distance of surgical margin by simulation and an actual measurement were 20.8±11.1 mm and 22.6±8.3 mm, respectively( p=0.186). Postoperative recurrence was found in 8 cases (distant in 7 and mediastinal lymph node in 1). No locoregional recurrence was found in all cases. Postoperative recurrence was similar between the 2 groups in active and passive limited resection, respectively. CONCLUSION: ICG-guided sublobar resection by transbronchial ICG instillation is applicable to any type of sublobar resection and can control local recurrence of lung neoplasms.
Subject(s)
Lung Neoplasms/surgery , Pneumonectomy , Fluorescence , Humans , Imaging, Three-Dimensional , Indocyanine Green , Neoplasm Recurrence, LocalABSTRACT
PURPOSES: To evaluate vertebral artery (VA) dominancy and the risk of brain infarction in T4 lung cancer patients with tumor invasion into the subclavian artery. METHODS: We reconstructed the subclavian artery in 10 patients with T4 non-small cell lung cancer. The histological stages were IIIA in eight patients and IIIB in two patients. We evaluated the VA dominancy by performing a four-vessel study preoperatively and investigated the relationship between the methods of VA treatment and postoperative brain complications, retrospectively. RESULTS: Seven patients had a superior sulcus tumor (SST) and three had direct invasion into the mediastinum. Based on the tumor location, a transmanublial approach was used in five patients and a posterolateral hook incision was used in the other five. All subclavian artery (SA) reconstructions were done using an artificial woven graft. Preoperative angiography of the VA revealed poor development of the contralateral side in two patients. One of these patients suffered a severe brain infarction on postoperative day 2, which proved fatal. In the other patient, the VA was connected to the left SA graft by a side-to-end anastomosis and there was no postoperative brain complication. CONCLUSIONS: Preoperative SA and VA angiography is mandatory for identifying the need for VA reconstruction in lung cancer patients with major arterial invasion.
Subject(s)
Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Plastic Surgery Procedures , Subclavian Artery/pathology , Subclavian Artery/surgery , Vascular Neoplasms/pathology , Vascular Neoplasms/surgery , Vascular Surgical Procedures , Vertebral Artery/surgery , Adult , Aged , Brain Infarction/etiology , Brain Infarction/prevention & control , Female , Humans , Magnetic Resonance Angiography , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Retrospective Studies , Risk , Subclavian Artery/diagnostic imaging , Tomography, X-Ray Computed , Treatment Outcome , Vertebral Artery/diagnostic imagingABSTRACT
OBJECTIVE: We investigated the effects of testosterone replacement therapy (TRT) on bone mineral density (BMD) among hypogonadal men with osteopenia/osteoporosis. METHODS: From our previous EARTH study population, 74 patients with a clinical diagnosis of osteopenia or osteoporosis and hypogonadism were included in this study, as the TRT (n = 35) and control (n = 34) groups. The TRT group was administered 250 mg of testosterone enanthate injection every 4 weeks for 12 months. The BMD, waist circumference, body mass index, body fat percentage, and muscle volume were measured at baseline and at 12 months. Blood biochemical data, including total cholesterol, triglycerides, HDL-cholesterol, hemoglobin A1c, and adiponectin values were also evaluated. RESULTS: At the 12-month visit, BMD significantly increased in both groups. However, comparisons on changes of parameter values from baseline to the 12-month visit between the TRT and control groups were significantly different in BMD (5.0 ± 5.0 vs. 3.0 ± 3.2; p = .0434) and in adiponectin value (-0.90 ± 3.33 vs. 0.10 ± 2.04; p = .0192). There were no significant changes in other parameters. CONCLUSIONS: TRT for 12 months could improve BMD with a decrease in adiponectin levels among hypogonadal men with osteopenia/osteoporosis.
Subject(s)
Androgens/administration & dosage , Bone Density/drug effects , Hormone Replacement Therapy/methods , Hypogonadism/drug therapy , Osteoporosis/drug therapy , Testosterone/analogs & derivatives , Adiponectin/blood , Aged , Case-Control Studies , Humans , Hypogonadism/blood , Hypogonadism/complications , Injections, Intramuscular , Japan , Male , Middle Aged , Osteoporosis/blood , Osteoporosis/complications , Prospective Studies , Statistics, Nonparametric , Testosterone/administration & dosageABSTRACT
Malignant mesothelioma is a highly aggressive neoplasm, and the histologic subtype is one of the most reliable prognostic factors. Some biphasic mesotheliomas are difficult to distinguish from epithelioid mesotheliomas with atypical fibrous stroma. The aim of this study was to analyze p16/CDKN2A deletions in mesotheliomas by fluorescence in situ hybridization (FISH) and BAP1 immunohistochemistry to evaluate their potential role in the diagnosis of biphasic mesothelioma. We collected 38 cases of pleural mesotheliomas. The results of this study clearly distinguished 29 cases of biphasic mesothelioma from 9 cases of epithelioid mesothelioma. The proportion of biphasic mesotheliomas with homozygous deletions of p16/CDKN2A in total was 96.6% (28/29). Homozygous deletion of p16/CDKN2A was observed in 18 (94.7%) of 19 biphasic mesotheliomas with 100% concordance of the p16/CDKN2A deletion status between the epithelioid and sarcomatoid components in each case. Homozygous deletion of the p16/CDKN2A was observed in 7 (77.8%) of 9 epithelioid mesotheliomas but not in fibrous stroma. BAP1 loss was observed in 5 (38.5%) of 13 biphasic mesotheliomas and in both epithelioid and sarcomatoid components. BAP1 loss was observed in 5 (62.5%) of 8 epithelioid mesotheliomas but not in fibrous stroma. Homozygous deletion of p16/CDKN2A is common in biphasic mesotheliomas, and the analysis of only one component of mesothelioma is sufficient to show that the tumor is malignant. However, compared with histology alone, FISH analysis of the p16/CDKN2A status and BAP1 immunohistochemistry in the spindled mesothelium provide a more objective means to differentiate between biphasic mesothelioma and epithelioid mesothelioma with atypical stromal cells.
Subject(s)
Cyclin-Dependent Kinase Inhibitor p18/genetics , Mesothelioma/diagnosis , Mesothelioma/genetics , Pleural Neoplasms/diagnosis , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics , Aged , Biomarkers, Tumor/analysis , Cyclin-Dependent Kinase Inhibitor p16 , Diagnosis, Differential , Female , Humans , Immunohistochemistry/methods , In Situ Hybridization, Fluorescence/methods , Male , Middle Aged , Pleural Neoplasms/geneticsABSTRACT
This study analyzed the effects of dutasteride on lower urinary tract symptoms based on the association between changes in the total testosterone (TT)/dihydrotestosterone (DHT) levels and total prostate volume (TPV) reduction. Sixty participants diagnosed with benign prostatic hyperplasia were given 0.5 mg of dutasteride daily for 52 weeks. Measures of TT and DHT levels, TPV and uroflowmetry were obtained before and after dutasteride treatment. Forty-three patients demonstrated a TPV reduction of ≥5% (Group 1), whereas the remaining 17 patients demonstrated a TPV reduction of <5% (Group 2). DHT suppression and DHT/TT ratio at baseline were significantly higher in Group 1 than Group 2. International Prostate Symptom Scores (IPSS) and uroflowmetry were significantly improved in both groups. In Group 2, nine patients demonstrated some improvement in IPSS (Group 2A), whereas eight did not (Group 2B). The rate of TT increase and improvement in voiding symptoms were significantly higher in Group 2A than Group 2B. Dutasteride-induced TPV reduction is dependent on individual 5-α reductase inhibitor activity. Some patients demonstrating smaller dutasteride-induced TPV reduction may experience an improvement in voiding symptoms owing to an increased level of testosterone.
Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Dihydrotestosterone/blood , Dutasteride/therapeutic use , Lower Urinary Tract Symptoms/drug therapy , Prostate/drug effects , Prostatic Hyperplasia/drug therapy , Testosterone/blood , 5-alpha Reductase Inhibitors/pharmacology , Dutasteride/pharmacology , Humans , Lower Urinary Tract Symptoms/etiology , Male , Organ Size/drug effects , Prospective Studies , Prostate/pathology , Prostatic Hyperplasia/complicationsABSTRACT
Sex chromosome inactivation is essential epigenetic programming in male germ cells. However, it remains largely unclear how epigenetic silencing of sex chromosomes impacts the evolution of the mammalian genome. Here we demonstrate that male sex chromosome inactivation is highly conserved between humans and mice and has an impact on the genetic evolution of human sex chromosomes. We show that, in humans, sex chromosome inactivation established during meiosis is maintained into spermatids with the silent compartment postmeiotic sex chromatin (PMSC). Human PMSC is illuminated with epigenetic modifications such as trimethylated lysine 9 of histone H3 and heterochromatin proteins CBX1 and CBX3, which implicate a conserved mechanism underlying the maintenance of sex chromosome inactivation in mammals. Furthermore, our analyses suggest that male sex chromosome inactivation has impacted multiple aspects of the evolutionary history of mammalian sex chromosomes: amplification of copy number, retrotranspositions, acquisition of de novo genes, and acquisition of different expression profiles. Most strikingly, profiles of escape genes from postmeiotic silencing diverge significantly between humans and mice. Escape genes exhibit higher rates of amino acid changes compared with non-escape genes, suggesting that they are beneficial for reproductive fitness and may allow mammals to cope with conserved postmeiotic silencing during the evolutionary past. Taken together, we propose that the epigenetic silencing mechanism impacts the genetic evolution of sex chromosomes and contributed to speciation and reproductive diversity in mammals.
Subject(s)
Chromatin/genetics , Chromosomes, Human, Y/genetics , Evolution, Molecular , Meiosis , Animals , Chromatin/metabolism , Chromobox Protein Homolog 5 , Chromosomes, Human, Y/metabolism , Epigenesis, Genetic , Gene Dosage , Gene Expression Profiling , Genes, X-Linked , Humans , Male , Mice , Oligonucleotide Array Sequence Analysis , Spermatogenesis/genetics , Spermatogonia/metabolism , Transcription, GeneticABSTRACT
OBJECTIVE: We investigated the effects of testosterone replacement therapy (TRT) on nocturia and general health among men with hypogonadism and nocturia. METHODS: From our previous EARTH study population, 64 patients with a clinical diagnosis of nocturia (two or more times per one night) and hypogonadism, comprising the TRT group (n = 31) and controls (n = 33), were included in this analysis. The TRT group was administered 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months. All patients responded to the following questionnaires: International Prostatic Symptoms Score (IPSS), Aging Male Symptoms (AMS) score and Short Form-36 health survey at baseline and 6-month visit. These categories were compared based on changes from baseline to the 6-month visit between TRT and control groups. RESULTS: At the 6-month visit, the TRT group had a significant decrease in IPSS question no. 7 and AMS question no. 4, whereas no significant changes were observed in the control group. Additionally, role limitation because of health program, vitality and mental health domains were significantly improved in the TRT group. CONCLUSIONS: Six-month TRT may improve nocturia, sleep conditions and quality of life among men with hypogonadism and nocturia.
Subject(s)
Androgens/administration & dosage , Hormone Replacement Therapy , Hypogonadism/drug therapy , Nocturia/drug therapy , Testosterone/analogs & derivatives , Aged , Aged, 80 and over , Aging , Humans , Hypogonadism/complications , Japan , Male , Middle Aged , Nocturia/complications , Prospective Studies , Quality of Life , Surveys and Questionnaires , Testosterone/administration & dosageABSTRACT
INTRODUCTION: We investigated the effects of the relative increase in testosterone by dutasteride administration in patients with benign prostatic hyperplasia and hypogonadism on urinary symptoms or androgen-responsive general health. METHODS: Seventy-six patients were enrolled, and were taking 0.5 mg dutasteride daily for 52 weeks. Before and after treatment, all participants underwent blood test, and body mass index, prostate volume (PV), bone mineral density (BMD), post-voiding residual (PVR) volume, and muscle volume were measured. All patients responded to the questionnaires: International prostatic symptom score (IPSS), Overactive Bladder Symptom score (OABSS). Patients were divided into two groups according to the increase rate of total testosterone (TT): group A, ≥20% increase in TT level; group B, <20% increase or decrease. RESULTS: Baseline TT and free testosterone (FT) levels were significantly lower in group A than group B. Both groups showed marked improvement in PV and PVR. Group A showed significant improvement in IPSS and OABSS with a significant increase of FT level, whereas group B showed no significant change. Dutasteride treatment contributed to a significant increase in BMD in group A. CONCLUSIONS: Dutasteride treatment significantly improved urinary symptoms and BMD in patients with low baseline serum TT and FT levels.
Subject(s)
Azasteroids/therapeutic use , Hypogonadism/drug therapy , Lower Urinary Tract Symptoms/drug therapy , Prostatic Hyperplasia/drug therapy , Urological Agents/therapeutic use , Aged , Aged, 80 and over , Bone Density/drug effects , Dutasteride , Humans , Male , Middle Aged , Prospective Studies , Testosterone/blood , Treatment OutcomeABSTRACT
An 80-year-old man underwent right upper lobectomy for the resection of multiple cysts accompanied by a nodule. The pathological diagnosis was adenocarcinoma with surrounding atypical epithelial cell proliferation in a Type 1 congenital cystic adenomatoid malformation/congenital pulmonary airway malformation. There was epidermal growth factor receptor mutation in the adenocarcinoma and surrounding atypical epithelial cells that had proliferated. Malignant transformation of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation may be related to the epidermal growth factor receptor pathway in this case, with atypical epithelial cell proliferation as a precursor. We emphasize the importance of complete resection of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation and the possibility of treatment with epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutated cases.
Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Cell Transformation, Neoplastic , Cystic Adenomatoid Malformation of Lung, Congenital/pathology , ErbB Receptors/genetics , Lung Neoplasms/drug therapy , Lung Neoplasms/surgery , Mutation , Protein Kinase Inhibitors/therapeutic use , Protein-Tyrosine Kinases/antagonists & inhibitors , Adenocarcinoma/genetics , Adenocarcinoma of Lung , Aged, 80 and over , Humans , Lung Neoplasms/genetics , MaleABSTRACT
Patients with malignant mesothelioma typically present with a pleural effusion or pleural thickening and masses. A rare autopsy case of mesothelioma presenting with multiple bilateral lung nodules without clinically detectable pleural lesions is presented. A definitive diagnosis of the video-assisted thoracic surgery specimen could not be made, though a pattern of fibrosis mimicking organizing pneumonia was identified. Despite corticosteroid therapy, follow-up chest computed tomography showed enlargement of multiple nodules accompanied by the appearance of pleural thickening and effusions. The patient died of respiratory failure 11 months after initial presentation. Autopsy and retrospective analysis of the video-assisted thoracic surgery specimen using a p16 fluorescence in situ hybridization assay showed p16 homozygous deletion. The final diagnosis was sarcomatoid mesothelioma, and the lung nodules were intrapulmonary metastases from a clinically undetectable pleural sarcomatoid mesothelioma. It is important both to consider the possibility of mesothelioma with unusual clinical, radiological and pathological presentations and to remember that p16 fluorescence in situ hybridization analysis can play an important role in the diagnosis of mesothelioma.
Subject(s)
Lung Neoplasms/pathology , Mesothelioma/pathology , Pleural Neoplasms/pathology , Aged , Autopsy , Diagnosis, Differential , Humans , In Situ Hybridization, Fluorescence , Male , Mesothelioma, Malignant , Tomography, X-Ray ComputedABSTRACT
An interlaboratory comparison study for melatonin, cortisol and testosterone in saliva in which five laboratories participated is reported in this study. Each laboratory blindly measured eight samples prepared from natural saliva spiked with melatonin, cortisol and testosterone in the range 0-579 pmol/L for melatonin, 0-90 nmol/L for cortisol, and 0-622 pmol/L for testosterone. The recovery of spiked material for melatonin ranged from 91-110%, from 83-100% for cortisol and from 80-94% for testosterone. The content of natural hormone in saliva was estimated to be between 0.278 and 6.90 pmol/L for melatonin, 0.56 and 6.72 nmol/L for cortisol and 11.9 and 73.8 pmol/L for testosterone. This indicates a large interlaboratory variation. The present study emphasizes the importance of external quality control for the analysis of melatonin, cortisol and testosterone in saliva.
Subject(s)
Hydrocortisone/metabolism , Melatonin/metabolism , Saliva/metabolism , Testosterone/metabolism , Chromatography, Liquid , Enzyme-Linked Immunosorbent Assay/standards , Female , Humans , Hydrocortisone/isolation & purification , Laboratory Proficiency Testing , Melatonin/isolation & purification , Reference Standards , Tandem Mass Spectrometry/standards , Testosterone/isolation & purificationABSTRACT
PURPOSE: The purpose of this study was to determine the impact of pulmonary fibrosis (PF) on postoperative complications and on long-term survival after surgical resection in lung cancer patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: A retrospective chart review was conducted of 380 patients with COPD who had undergone pulmonary resection for lung cancer at the University Hospital between 1990 and 2005. The definition of COPD was a preoperative forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio of less than 70%; PF was defined as obvious bilateral fibrous change in the lower lung fields, confirmed by computed tomography. RESULTS: PF was present in 41 patients (10.8%) with COPD; the remaining 339 patients (89.2%) did not have PF. The preoperative FVC/FEV1 was significantly lower in the group of patients with PF than in the group without (p < 0.05). Acute lung injury and home oxygen therapy were significantly more common in the PF group; however, the 30-day mortality was similar between the groups. The cumulative survival at 3 and 5 years was 53.6 and 36.9%, respectively, in the PF group and 71.4 and 66.1%, respectively, in the non-PF group (p = 0.0009). Increased age, decreased body mass index, advanced pathologic stage, and the existence of PF were identified as independent risk factors for decreased survival. CONCLUSION: PF is a risk factor for decreased survival after surgical treatment in lung cancer patients with COPD.
Subject(s)
Lung Neoplasms/surgery , Lung/surgery , Pneumonectomy , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Fibrosis/complications , Aged , Female , Forced Expiratory Volume , Hospitals, University , Humans , Japan , Kaplan-Meier Estimate , Lung/pathology , Lung/physiopathology , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Lung Neoplasms/physiopathology , Male , Middle Aged , Pneumonectomy/adverse effects , Pneumonectomy/mortality , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/physiopathology , Pulmonary Fibrosis/diagnosis , Pulmonary Fibrosis/mortality , Pulmonary Fibrosis/physiopathology , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Vital CapacityABSTRACT
Primary pericardial synovial sarcoma is a rare disease. We herein report a case of synovial sarcoma that originated in the epicardium. A 13-year-old male visited our hospital with a fever and chest pain. Copious pericardial effusion and a large intrapericardial tumor were detected. An open-chest tumor resection was performed. A solid nodular tumor was observed in the pericardial cavity. The tumor was a polypoid mass that was pedunculated and grew from the inner surface of the pericardium near the origin of the SVC and ascending aorta. Histologically, the tumor cells were uniformly spindle shaped, with an ovoid or oval nucleus, and formed solid, compact sheets and fascicles. A storiform pattern was also observed. Based on the histopathological and immunohistochemical findings, and the fluorescence in situ hybridization detection of rearrangement of the SYT gene, a monophasic synovial sarcoma was diagnosed. We discuss the diagnosis and treatment of this case and review the pertinent literature.
Subject(s)
Heart Neoplasms/diagnosis , Heart Neoplasms/surgery , Pericardium , Sarcoma, Synovial/diagnosis , Sarcoma, Synovial/surgery , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cardiac Surgical Procedures , Chemotherapy, Adjuvant , Doxorubicin/administration & dosage , Gene Rearrangement , Heart Neoplasms/genetics , Heart Neoplasms/pathology , Humans , Ifosfamide/administration & dosage , Male , Proto-Oncogene Proteins/genetics , Repressor Proteins/genetics , Sarcoma, Synovial/genetics , Sarcoma, Synovial/pathology , Treatment OutcomeABSTRACT
OBJECTIVES: Deletions in the azoospermia factor regions are the most common known molecular genetic cause of human male infertility involving spermatogenetic failure. Testing for these deletions in Japanese DNA samples using conventional sequence-tagged site probes occasionally lead to considerable non-specific or faint products in the Japanese population. The aim of the present study was to evaluate the sensitivity and specificity of a newly developed kit for the detection of azoospermia factor microdeletions in the Japanese population. METHODS: Sequence-tagged site probes were reselected and the Luminex suspension array assay was carried out. Validation was retrospectively carried out with 2014 DNA sequences with known microdeletions, which were divided into four categories. RESULTS: Category 1 deletions that corresponded to the conventional classification of azoospermia factor deletion were present in 83 men (4.2%), which can result in intrachromosomal homologous recombination. Kit data confirmed the presence of deletions of this type in DNA sequences known to harbor the azoospermia factor deletions. Category 2 deletions involved cytogenetic abnormalities in 28 men (1.4%), whereas category 3 deletions in 759 men (37.7%) were atypical classifications including the gr/gr deletion. As these deletions are thought to be a result of palindromic units and non-homologous recombination, these microdeletions might impact in the interpretation of some clinical findings. The rest of the 1145 cases (56.8%) were assigned to category 4 as normal variants (polymorphism/no deletion). CONCLUSIONS: The present findings show that this new kit offers good sensitivity and specificity with the advantage of saving in terms of cost and time.
Subject(s)
Molecular Diagnostic Techniques , Sex Chromosome Disorders of Sex Development/diagnosis , Adult , Aged , Asian People , Chromosome Deletion , Chromosomes, Human, Y , Humans , Infertility, Male , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Sex Chromosome Aberrations , Young AdultABSTRACT
OBJECTIVES: To determine testosterone fractions in Japanese men and to compare these values with those of Framingham Heart Study participants. METHODS: We enrolled 498 healthy Japanese men. Total testosterone was assayed by liquid chromatography tandem mass spectrometry, sex hormone-binding globulin was assayed by immunoassay and free testosterone was calculated by a laboratory at the Boston Medical Center. Analog-based free testosterone and immunoassay-based total testosterone were determined by immunoassay. We compared mass spectrometry assay-based total testosterone and calculated free testosterone values in the Japanese participants with values in the American Framingham Heart Study third generation cohort. RESULTS: The mean serum mass spectrometry assay-based total testosterone, sex hormone-binding globulin, and calculated free testosterone values were 439.4 ± 167 ng/dL, 65.34 ± 30.61 nmol/L, and 58.75 ± 20.0 pg/mL, respectively. The correlation coefficients with age for mass spectrometry assay-based total testosterone, sex hormone-binding globulin, and calculated free testosterone were 0.0010, 0.5041, and -0.496, respectively. There were no age-related changes in mass spectrometry assay-based total testosterone values in healthy men (P = 0.981), whereas sex hormone-binding globulin and calculated free testosterone levels showed similar age-related changes (P < 0.0001). Serum analog-based free testosterone levels (8.24 ± 2.9 pg/mL) showed age-related changes (P < 0.0001) regardless of immunoassay-based total testosterone levels (P = 0.828). Serum immunoassay-based total testosterone values (486.1 ± 162.5 ng/dL) correlated with serum mass spectrometry assay-based total testosterone values (r = 0.740, 95% confidence interval 0.6965-0.7781, P < 0.0001). Similarly, analog-based free testosterone and calculated free testosterone values showed a highly significant correlation (r = 0.706, 95% confidence interval 0.6587-0.7473, P < 0.0001). The analog-based free testosterone values were approximately 10% of the calculated free testosterone values. CONCLUSIONS: In contrast to the Framingham Heart Study cohort, total testosterone values in Japanese men are not associated with advancing age; thus, they cannot be used to diagnose late-onset hypogonadism in Japan. The analog-based free testosterone value can be considered instead as a suitable biochemical determinant for diagnosing late-onset hypogonadism syndrome.
Subject(s)
Asian People/statistics & numerical data , Eunuchism/ethnology , Sex Hormone-Binding Globulin/metabolism , Testosterone/blood , White People/statistics & numerical data , Adult , Age Distribution , Age of Onset , Aged , Aged, 80 and over , Cohort Studies , Dehydroepiandrosterone/blood , Dihydrotestosterone/blood , Humans , Japan/epidemiology , Male , Massachusetts/epidemiology , Middle AgedABSTRACT
OBJECTIVE: The purpose was to determine the rates of postoperative pulmonary complications, and to clarify the impact of COPD on long-term survival in lung cancer patients after surgical resection. METHODS: A retrospective chart review was performed on 1,461 patients who had undergone pulmonary resection for lung cancer from 1990 to 2005. Classification of COPD severity was based on spirometric guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Postoperative complication rates among the four COPD groups were compared and long-term overall and disease-specific survivals were analyzed. RESULTS: The frequencies of all pulmonary complications in three COPD groups were higher than in the non-COPD group (all p < 0.05). Overall and disease-specific survivals were significantly worse in relation to higher COPD grades (all p ≤ 0.05). Significant prognostic factors were age, body mass index, positive smoking history, tumor size, pneumonectomy, pathologic stage, and COPD grade (p < 0.05). CONCLUSION: Higher COPD grades had higher rates of postoperative pulmonary complications and poorer long-term survivals because of higher rates of cancer-related deaths.
Subject(s)
Lung Neoplasms/surgery , Pneumonectomy , Pulmonary Disease, Chronic Obstructive/epidemiology , Aged , Chi-Square Distribution , Female , Humans , Japan/epidemiology , Kaplan-Meier Estimate , Lung Neoplasms/epidemiology , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Pneumonectomy/adverse effects , Pneumonectomy/mortality , Postoperative Complications/epidemiology , Postoperative Complications/mortality , Predictive Value of Tests , Prevalence , Proportional Hazards Models , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/physiopathology , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Spirometry , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: Intramuscular hemangioma (IMH) is an uncommon type of hemangioma, and primary IMH of the intercostal muscle is even rarer. Only a few reports describe IMH of the intercostal muscle, and there are no review articles on this topic. We report our experience with a younger female patient, who underwent video-assisted thoracic surgery with tumor resection and review the previous literatures of intercostal IMH. CASE PRESENTATION: An asymptomatic 17-year-old woman showed a 29-mm, homogeneous, intrathoracic nodule in the left chest wall, attached to the second and third ribs on computed tomography. We performed exploratory thoracoscopic surgery and the tumor was excised without surrounding rib resection. Histopathologic examination of the surgical specimen revealed proliferation of small blood vessels within the surrounding striated muscle, leading to the diagnosis of intercostal IMH. The surgical margin was negative. The patient's postoperative course was uneventful, and there has been no evidence of recurrence for more than 18 months after surgery. CONCLUSIONS: We describe a case of intercostal IMH, who received tumor resection with clear excision margin without surrounding rib resection. Preoperative diagnosis is challenging due to its rarity, but intercostal IMH should be recalled as a differential diagnosis of chest wall tumor. Tumor excision without surrounding rib resection is acceptable for intercostal IMH, when there is a good possibility of achieving negative surgical margin.
Subject(s)
Hemangioma , Thoracic Wall , Humans , Female , Adolescent , Hemangioma/diagnostic imaging , Hemangioma/surgery , Diagnosis, Differential , Tomography, X-Ray Computed , Thoracic Surgery, Video-Assisted , Thoracic Wall/surgery , Thoracic Wall/pathologyABSTRACT
It is well known that chronic obstructive pulmonary disease (COPD) is a significant risk factor for lung cancer. Approximately 1% of COPD patients develop lung cancer every year, which may be associated with genetic susceptibility to cigarette smoke. Chronic inflammation caused by toxic gases can induce COPD and lung cancer. Inflammatory mediators may promote the growth of bronchioalveolar stem cells, and activation of nuclear factor-κB and signal transducer and activator of transcription 3 play crucial roles in the development of lung cancer from COPD. Low-dose computed tomography (LDCT) is an effective procedure for the early detection of lung cancer in high-risk patients. However, determining which patients should be screened for lung cancer in a primary care setting is difficult. In this article, we review the epidemiology and aetiology of lung cancer associated with COPD, verify the efficacy of lung cancer screening by LDCT, and discuss the importance of early detection of COPD for lung cancer surveillance. We propose that, for the prevention of both diseases, COPD screening in smokers should be initiated as early as possible, so they can stop smoking and so that candidates for an efficient lung cancer screening programme can be identified.
Subject(s)
Adenocarcinoma/diagnosis , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Squamous Cell/diagnosis , Lung Neoplasms/diagnosis , Pulmonary Disease, Chronic Obstructive/diagnosis , Adenocarcinoma/epidemiology , Adenocarcinoma/genetics , Adenocarcinoma of Lung , Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/genetics , Comorbidity , Early Detection of Cancer , Female , Genetic Predisposition to Disease , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/genetics , Male , Prognosis , Risk Factors , Smoking/adverse effects , Smoking/epidemiologyABSTRACT
OBJECTIVE: To examine whether bone turnover markers could be predictive markers of the probability of newly arising skeletal-related events (SRE) after the start of zoledronic acid treatment in patients with prostate cancer with bone metastasis. PATIENTS AND METHODS: In all, 30 patients with prostate cancer with bone metastasis were treated with zoledronic acid infusion every 4 weeks. Serum C-terminal crosslinking telopeptide of type 1 collagen (1CTP), bone alkaline phosphatase (BAP), and prostate-specific antigen (PSA) levels were measured at the start of zoledronic acid treatment to establish baseline values, and every 4 weeks thereafter. To judge in the early phase whether zoledronic acid is effective in these patients, we retrospectively compared 1CTP, BAP, and PSA levels at 1, 3, and 6 months after starting zoledronic acid treatment with those at baseline. RESULTS: SRE-free survival of patients with increases of 1CTP levels at 1 and 3 months and BAP levels at 3 months were significantly poorer than those of patients with decreases in 1CTP or BAP levels (P = 0.001, P = 0.042, and P = 0.004, respectively). Overall survival of patients with increases of 1CTP levels at 1 and 3 months and of BAP levels at 6 months were significantly poorer than those of patients with decreases of 1CTP or BAP levels (P = 0.013, P = 0.027, and P = 0.035, respectively). CONCLUSION: The measurement of 1CTP and BAP levels at an early phase after starting zoledronic acid treatment may be useful for physicians to inform patients of their prognosis and to determine the subsequent treatment plan.